Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
Key Highlights
- ➤Exicure agrees to sell GPC-100 assets to GPCRT for KRW 6.5 billion.
- ➤KRW 2.0 billion is payable by November 16, 2026; KRW 4.0 billion at closing.
- ➤GPCRT assumes future GPC-100 milestone, royalty, contract, and post-September 1 costs.
- ➤Closing requires approvals and consents, with no assurance the transaction will complete.
- ➤Exicure expects the sale to strengthen its financial position and support strategic alternatives.
WILMINGTON, Del., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that on November 4, 2026, the Company and its wholly owned subsidiary, GPCR Therapeutics USA Inc. (“GPCR USA”), entered into an Intellectual Property, Asset and License Assignment Agreement (the “Agreement”) with GPCRT Inc. (“GPCRT”), a company organized under the laws of the Republic of Korea, under which GPCRT has agreed to acquire the Company’s GPC-100 (burixafor) program assets for an aggregate cash purchase price of KRW 6.5 billion (approximately US$4.8 million).
The assets to be sold consist of the Company’s rights under its License and Collaboration Agreement with GPCR Therapeutics, Inc. dated January 19, 2025, together with the related contracts, intellectual property, clinical and regulatory data, materials and equipment of the Company and GPCR USA used in the GPC-100 program. GPC-100 is being evaluated in combination with propranolol for stem cell mobilization in patients with multiple myeloma, and GPCR USA completed its Phase 2 clinical trial of GPC-100 in January 2026. GPCR USA will remain a wholly owned subsidiary of Exicure following the closing.
Get started
Create a free account to read the full story.